Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
During the five-year collaboration, the partners will research disease-causing gene mutations and develop new CRISPR-based technologies for drug discovery.
The FLASH method, which depletes unwanted DNA from samples, allows labs to perform deep metagenomic sequencing on smaller, less expensive instruments.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
Researchers found that hypoxia was associated with elevated genomic instability in 10 tumor types and saw widespread hypoxia-associated dysregulation of miRNAs.
With a DNA methylation atlas and deconvolution algorithm, researchers are attempting to trace cfDNA back to tissue sources in healthy or ill individuals.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.